Clene CSO granted 75,000 stock options

Clene Inc.'s Chief Science Officer, Mark Mortenson, received a new stock option grant.

Accepted by SEC EDGAR 01/23/2026 - 04:14 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Clene Inc.'s Chief Science Officer, Mark Mortenson, received a new stock option grant. On January 22, 2026, he was awarded options to purchase 75,000 shares of Clene Inc. common stock at an exercise price of $5.42 per share under the Clene Inc. Amended 2020 Stock Plan. The filing notes that these options vest immediately upon grant, meaning they are fully exercisable right away. Following this grant, Mortenson holds 75,000 derivative securities (stock options) directly.

Insider Trade Summary

Grant/Award: 75,000 shares

Grant/Award 1 txn

Insider Mortenson Mark

Role Chief Science Officer

Type	Security	Shares	Price	Value
Grant/Award	stock option	75,000	$0.00	$0.00

Holdings After Transaction: stock option — 75,000 contracts (Direct)

Footnotes (1)

1. F1. This option was granted on January 22, 2026 as an option for 75,000 share of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $5.42 per share. The options vest immediately upon grant.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock options did Clene (CLNN) grant to its Chief Science Officer?

On January 22, 2026, Clene Inc. granted its Chief Science Officer, Mark Mortenson, a stock option for 75,000 shares of common stock at an exercise price of $5.42 per share under the Clene Inc. Amended 2020 Stock Plan.

When do the new Clene (CLNN) stock options granted to the CSO vest?

According to the filing, the stock options granted to Chief Science Officer Mark Mortenson on January 22, 2026 vest immediately upon grant, making them fully exercisable right away.

What is the exercise price of the Clene (CLNN) stock options granted on January 22, 2026?

The stock options granted to Chief Science Officer Mark Mortenson on January 22, 2026 have an exercise price of $5.42 per share for Clene Inc. common stock.

How many derivative securities does the Clene (CLNN) CSO hold after this Form 4 transaction?

Following the reported transaction, Chief Science Officer Mark Mortenson beneficially owns 75,000 derivative securities (stock options) directly, as stated in the filing.

What plan governs the new stock option grant reported for Clene (CLNN)?

The option grant for 75,000 shares to Chief Science Officer Mark Mortenson was made under the Clene Inc. Amended 2020 Stock Plan, as specified in the footnote.

What is the expiration date of the Clene (CLNN) stock options granted to the CSO?

The stock options granted on January 22, 2026 to Chief Science Officer Mark Mortenson have an expiration date of January 21, 2036, with 75,000 underlying shares of common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mortenson Mark

(Last) (First) (Middle)

6550 SOUTH MILLROCK DRIVE

SUITE G50

(Street)

SALT LAKE CITY UT 84121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Clene Inc. [ CLNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Science Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
stock option	$5.42	01/22/2026		A		75,000		(1)	01/21/2036	common stock	75,000	$0	75,000	D

Explanation of Responses:

1. This option was granted on January 22, 2026 as an option for 75,000 share of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $5.42 per share. The options vest immediately upon grant.

	/s/ Jerome T. Miraglia POA	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.